When a crown, bridge, denture, or implant restoration gets rejected and fabricated again, we call it a remake. This dossier quantifies how often it happens, why, where, and how much it costs — using 60+ peer-reviewed and industry sources in English and Spanish.
Each number below is a data point we expand on in the rest of the report. Left to right: the top row shows scale, the middle row the root cause, the bottom row the economic impact.
The chart shows 12 studies and reports, each a data point on how often restorations get remade (or how often impressions arrive defective — the origin of the problem). Green = low rates, amber = industry average, red = high rates / defect zone. The dotted line at 4% marks the global modal rate.
The first three bars (<1% to 2.9%) correspond to elite digital labs and industry targets. The central block — 3.8% to 4% — represents the real-world average most operate at.
Everything red is a different kind of number: 86% and 97% aren't remake rates but the share of impressions arriving already defective. Same with 33.6% (5-year clinical complications in fixed bridges) and 32.97% (dentures with lab errors during fabrication).
Conclusion: 4% remakes is the tip of the iceberg. Far more cases contain defects than ever reach a remake, which means the prevention opportunity is much larger than that 4%.
When the case runs through a fully digital workflow — intraoral scan → cloud Rx → CAD design → CAM fabrication — the remake rate drops roughly 80%. The physical links that traditionally carry the errors disappear: impression material, tray pressure, shipping damage, handwritten prescriptions.
The decisive variable is the workflow itself — not the materials or the individual operator. Closing the surgeon↔lab handoff — the moment where 86% of impressions today show defects — explains most of this improvement.
TrazaLab's case-completeness gate acts at exactly that moment: it blocks the case from reaching fabrication until every protocol field is filled in. That's the structural reason digital workflows lose so few cases.
A defect is any observable error a lab inspector can flag in the received impression: a void at the margin, a pull, a tear, contamination, pressure distortion. Two landmark studies — one in Iceland/Austria, one in Yemen — photographed and scored every impression arriving at commercial labs. The results are devastating.
Defect rate ≠ remake rate. Clinicians fix many defects chairside without resending to the lab. But every defect is a remake risk, and the ones that end up as remakes are almost always margin-line errors.
If the industry could catch defects at the handoff (before fabrication starts) instead of at try-in (when the crown is already milled), the 4% rate would drop toward the <1% digital benchmark.
Each block is sized in proportion to its estimated share of the $2.7B annual total. The percentages reconcile data from NDPBRN (dentist-reported), Oyanguren 2003 (neutral audit at a university lab), Pjetursson 2012 (systematic review), and industry aggregates. Colors group causes by where they originate: red = chairside impression errors, amber = lab/communication, blue = clinical decisions, purple = material/implants.
Impression defects (35%), lab fabrication errors (22%), and surgeon↔lab communication failures (12%) together make up 69% of all remakes.
The first and third — over 47% of total volume — originate before the lab, in the clinic and in the handoff. These are the preventable causes. Fabrication defects (22%) are a separate quality-control problem inside the lab itself.
Patient-driven remakes are only 2%. The remaining 98% are structural, not aesthetic preference.
The global total is allocated in proportion to each region's revenue share of the dental-lab market (Grand View, MarketDataForecast, Fortune Business Insights). Spain is broken out separately because it's TrazaLab's home market — but its losses are already inside the EU total, not additive.
Spain alone loses ~€72M (~$78M) a year to remakes — roughly 14% of total lab-sector revenue. At a €450 average per remake, that's ~160,000 remakes per year across 1,500 labs — ~107 per lab per year.
Preventing one remake a week at a mid-sized lab = ~50 per year = ~€22,500 in annual savings per lab. TrazaLab's addressable market in Spain reaches that entire €72M pool.
Each horizontal bar represents one cause. The colors inside the bar show how global dollar losses distribute across regions. It's the same data as the mosaic above, now expressed in currency.
$945M — impression / margin-line errors. A single cause. Larger than the next two combined.
$594M — lab fabrication. CAD design, milling damage, sintering distortion, marginal fit.
$324M — lab ↔ surgeon communication. Missing Rx fields, undefined pontic design, mis-specified shade.
Together these three add up to $1.86 billion in preventable loss — and all three are addressable with a case-completeness protocol enforced before fabrication starts.
Each bubble is sized in proportion to the estimated annual remake loss for that treatment type. The model multiplies global unit volume × treatment-specific remake rate × mean all-in cost. Complete dentures carry the highest lab-error rate (32.97% — Juniper 2019). Full-arch implant prosthetics are low volume but cost ~$2,500 per remake.
A prevention tool that works across every treatment type captures the full $1.6B. A tool that only covers crowns captures 37%.
Complete dentures are the category with the highest error-rate leverage — they deserve outsized attention in any quality program: remaking a complete denture costs roughly 4× more than remaking a crown ($600 vs $150 in lab cost).
When a single crown has to be remade in the US, it costs on average $450 all-in. Here's how that spend breaks down. Chair time — hours of dentist and assistant work for re-prep, re-impression, re-cementation — is the biggest line.
The lab absorbs the $150 refabrication (often as warranty — no charge to the dentist). The clinic absorbs the $225 in lost chair time and $55 in patient comp. So the clinic loses $280 per remade crown while the lab loses $150.
Commercial implication: the clinic has the bigger direct financial incentive to prevent remakes — but the lab is usually the one seeing the patterns. TrazaLab makes the evidence visible to both sides.
When a remake happens, whose fault is it? Every study that asks this question gives a different answer depending on who's answering. The three cards show how the most authoritative datasets diverge — and why neutral case documentation (the core of TrazaLab) settles the debate.
The debate isn't about the numbers — it's about which evidence counts. The lab sees defective impressions but doesn't see the clinical judgment behind them. The dentist sees crowns that fail but doesn't see the lab's fabrication log.
A timestamped, auditable case history — protocol fields, photos, scans, Rx, and fabrication steps — eliminates the blame discussion entirely. TrazaLab isn't a tool that takes sides: it's the neutral source of truth that ends the debate and focuses both sides on prevention.
One point — from 4% to 3% — is what digital-workflow studies already document inside individual labs. Applied to the global 150M prosthetic units at $450 mean cost, this is the economic ceiling TrazaLab is built against.
Drop into a landing page, demo video, deck, or slide. Every line is backed by the full dossier sources.